NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00091676,Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma,https://clinicaltrials.gov/study/NCT00091676,BiovaxID,UNKNOWN,"The primary objective of this Phase 3 study is to definitively confirm the safety and efficacy of BiovaxId, an autologous tumor derived immunoglobulin idiotype vaccine, as measured by a significant prolongation of the period of disease free survival when administered to patients with indolent follicular Non-Hodgkin's Lymphoma (NHL) during their first complete remission.",NO,Non-Hodgkins Lymphoma,BIOLOGICAL: FNHLId1|BIOLOGICAL: KLH + GM-CSF,"To demonstrate prolongation of the period of Disease Free Survival (significant prolongation of the period of complete remission) in idiotype vaccine treated patients, until date of relapse","To determine the ability of the idiotype vaccine to produce a molecular complete remission, once subject achieves molecular CR|To determine the impact of molecular disease free survival, until relapse|To assess the ability of the idiotype vaccine to generate an immunologic response against the NHL tumor, varies|To compare the overall survival of subjects randomized to receive either treatment, minimum 5 years from last subject randomized|To confirm the safety of 5 monthly injections of the vaccine with GM-CSF, 4 days",,Biovest International,,ALL,"ADULT, OLDER_ADULT",PHASE3,629,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",BV 301,2000-01,2012-12,2012-12,2004-09-17,,2012-02-03,,
